Some cellular and pathophysiological correlates of the inflammatory effects of a synthetic immunomodulatory agent, muramyl dipeptide (MDP)
Language English Country Switzerland Media print
Document type Comparative Study, Journal Article
PubMed
8386899
DOI
10.1007/bf02027221
Knihovny.cz E-resources
- MeSH
- Acetylmuramyl-Alanyl-Isoglutamine toxicity MeSH
- Edema chemically induced MeSH
- Indomethacin pharmacology MeSH
- Capillary Permeability drug effects MeSH
- Drug Interactions MeSH
- Antibodies, Monoclonal immunology MeSH
- Mice, Inbred C57BL MeSH
- Mice, Nude MeSH
- Mice MeSH
- Silicon Dioxide pharmacology MeSH
- Stereoisomerism MeSH
- T-Lymphocytes immunology MeSH
- Dose-Response Relationship, Drug MeSH
- Hindlimb MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- Acetylmuramyl-Alanyl-Isoglutamine MeSH
- Indomethacin MeSH
- Antibodies, Monoclonal MeSH
- Silicon Dioxide MeSH
Acute, fully reversible paw edema was produced in mice after systemic administration of muramyl dipeptide (MDP, i.e. N-acetylmuramyl-L-alanyl-D-isoglutamine). Its stereoisomer N-acetylmuramyl-D-alanyl-D-isoglutamine (MDP-D,D) was much less effective. The swelling of paws occurred very soon (1 h) after MDP injection, reached the maximum severity at an interval of 6 h and declined afterwards. While no substantial quantitative differences were found in the sensitivity of the various inbred strains of mice to edemagenic activity of MDP, athymic nude mice were completely resistant to the induction of edema. Formation of edema was blocked by silica, indomethacin (partially also by nordihydroguaiaretic acid), monoclonal antibodies against T-cells and their TH-subpopulation. It is suggested that the MDP-induced edema is a macrophage- and T-cell-dependent, prostaglandin- (and partially leukotriene)-mediated acute reaction associated with increased vascular permeability. Possible engagement of immune/inflammatory cytokines like IL-1 has been discussed. The data support the view that this type of edema is a consequence of changes in the activity of important cellular components of the immune system.
See more in PubMed
Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):419-26 PubMed
J Infect Dis. 1980 Nov;142(5):708-15 PubMed
J Immunol. 1984 Oct;133(4):1996-2000 PubMed
Int J Immunopharmacol. 1979;1(1):35-41 PubMed
Ann N Y Acad Sci. 1971 Apr 30;180:338-50 PubMed
J Immunol. 1987 Apr 1;138(7):2124-31 PubMed
Immunobiology. 1988 Jul;177(3):305-16 PubMed
Int J Immunopharmacol. 1986;8(5):487-98 PubMed
Ann R Coll Surg Engl. 1978 May;60(3):198-201 PubMed
Eur J Immunol. 1984 Oct;14(10):898-901 PubMed
Agents Actions. 1976 Nov;6(6):705-11 PubMed
Infect Immun. 1982 Sep;37(3):1181-90 PubMed
Int J Immunopharmacol. 1982;4(5):451-62 PubMed
Arch Int Pharmacodyn Ther. 1983 Feb;261(2):316-27 PubMed
J Immunol. 1979 Jun;122(6):2226-31 PubMed
Nature. 1977 Dec 8;270(5637):530-2 PubMed
Microbiol Immunol. 1981;25(1):41-50 PubMed
J Clin Invest. 1986 Mar;77(3):1020-7 PubMed
Infect Immun. 1983 Dec;42(3):1081-5 PubMed
Infect Immun. 1982 Feb;35(2):674-9 PubMed
Annu Rev Immunol. 1984;2:335-57 PubMed
Annu Rev Immunol. 1986;4:369-88 PubMed
N Engl J Med. 1983 Mar 10;308(10):553-8 PubMed
Microbiol Immunol. 1986;30(7):717-23 PubMed
Proc Natl Acad Sci U S A. 1978 Jun;75(6):2955-8 PubMed
Arch Immunol Ther Exp (Warsz). 1989;37(5-6):587-92 PubMed
Cell Immunol. 1980 Mar 1;50(1):71-81 PubMed
